Cipher Pharmaceuticals Appoints New President and General Manager of US Business
Cipher Pharmaceuticals Inc. named Ralph Bohrer as President and General Manager of its US subsidiary. Mr. Bohrer is a seasoned pharmaceutical executive with 30 years of experience in sales and marketing leadership for growing dermatology companies.
Prior to joining Cipher, he was Executive Director, Sales and Marketing of Taro Pharma, a global leader in the development, manufacture and sale of dermatology products. In this role, he was responsible for all aspects of their branded dermatology business unit for Taro Pharmaceutical Industries. Previously, he was Vice President, Sales at Triax Pharmaceuticals (acquired by PreCision Dermatology in 2012), where he led a 60-person team responsible for the promotion and sale of a line of prescription dermatology products, including category leader Locoid® Lipocream and Lotion, Tretin X® and Minocin®. Mr. Bohrer was also Principal of Ridgeback Associates, a consulting business he founded to provide companies with insight and direction toward specific and measurable sales, marketing, and business development objectives within various pharmaceutical sectors. Prior to Ridgeback, he spent 14 years with Medicis Pharmaceutical in progressively senior positions, including President of Medicis Canada, and Senior Vice President, Sales, where he helped drive sales from inception to more than US$300 million while establishing and directing a 175-person sales organization. Prior to leaving Medicis, he was General Manager of Ascent Pediatrics/Ucyclyd Pharma, the pediatric and orphan drug subsidiaries of Medicis.
"We're building a fast-growing dermatology business, underpinned by a high-quality sales and marketing organization with a clear focus on the customer, and Ralph is a great addition to our organization," said Shawn Patrick O'Brien, President & CEO of Cipher. "He is a highly accomplished executive and has the sales leadership experience, industry knowledge and connections in the field to drive the growth of our current commercial products and the successful introduction of multiple new products we expect to bring to the market in the coming years."
"This is an exciting time to join the Cipher organization," said Mr. Bohrer. "There is a great opportunity for a new entrant in the dermatology space. In a short period of time, Cipher has established a commercial foothold with multiple promising assets – a solid platform from which to expand the business. I look forward to working with the team to deliver on the growth plan."